As SCD is consideredan inflammatory condition, Galectin-3 may be a potential targetfor intervention in the progression of disease process in SCD too.Galectin-3 inhibitor like GMI-1051 (GlycoMimetics) may be of usein hampering the inflammation in SCD. This evidence concerns the gene LGALS3 and Schnyder corneal dystrophy.